Jury Says Sandoz Owes $39M for Eyelash Drug Patent Infringement

A federal jury has ordered Novartis’ Sandoz subsidiary to pay $39 million in damages to Allergan and Duke University for infringement of patent rights for Allergan’s eyelash-enhancing therapy Latisse (bimatoprost).
Source: Drug Industry Daily